Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
Learn more about:
Related Clinical Trial
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
PRO1184 for Advanced Solid Tumors
A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
A Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma
AMT-151 in Patients With Selected Advanced Solid Tumours
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Stereotactic Magnetic Resonance Guided Radiation Therapy
Real World Study of MPM in China
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Cardiac MRI Biomarker Testing (GCC 1618)
UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Alvopem® (Pemetrexed) Safety Assessment
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Olaparib in Patients With HRD Malignant Mesothelioma
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Intravenous Magnesium in Patients Receiving Cisplatin
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Transitions Project
High Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
18F-FSPG PET/CT for Cancer Patients on Therapy
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Molecular Analysis of Thoracic Malignancies
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Amatuximab for High Mesothelin Cancers
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
First-in-human Study of S-588210 (S-488210+S-488211)
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Rapid Autopsy and Procurement of Cancer Tissue
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
Mithramycin for Lung, Esophagus, and Other Chest Cancers
APG-2449 in Patients With Advanced Solid Tumors
CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
A Study of LY3023414 in Participants With Advanced Cancer
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Dose Individualization of Pemetrexed – IMPROVE-III
Dose Individualization of Pemetrexed – IMPROVE-II
Dose Individualization of Pemetrexed – IMPROVE-I
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Gefitinib in Treating Patients With Malignant Mesothelioma
DENdritic Cell Immunotherapy for Mesothelioma
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Sorafenib in Previously Treated Malignant Mesothelioma
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Capecitabine in Treating Patients With Malignant Mesothelioma
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Olaparib in People With Malignant Mesothelioma
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
IP3R Modulation by Cancer Genes in Mesothelioma
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung
Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
SU5416 in Treating Patients With Malignant Mesothelioma
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Autologous Redirected RNA Meso-CIR T Cells
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
Tomotherapy Treatment for Mesothelioma
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Mesothelioma and Radical Surgery 2
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
Isolated Thoracic Perfusion (ITP-F) for MPM
Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
Nivolumab in Patients With Recurrent Malignant Mesothelioma
Serum Biomarkers in Diagnosis of Mesothelioma
Short Neoadjuvant Hemithoracic IMRT for MPM
Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Four Versus Six Cycles of Pemetrexed/Platinum for MPM
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
Nintedanib (BIBF 1120) in Mesothelioma
Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
Vinorelbine in Mesothelioma
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
S0509 – AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Intrapleural Gene Transfer for Pleural Mesothelioma
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Combination Gene Transfer and Chemotherapy
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma
The IMmunotherapy Pleural 5-ALA PDT
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
Dendritic Cell-based Immunotherapy in Mesothelioma
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Trimodality Therapy for Malignant Pleural Mesothelioma
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas
Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma
Dasatinib in Resectable Malignant Pleural Mesothelioma
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
ATREUS – Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
Pembrolizumab + Defactinib In Pleural Mesothelioma
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Response Evaluation in Malignant Pleural Mesothelioma
Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma